Corticosteroid therapy in TSP/HAM patients: The results from a 10 years open cohort

Journal of the Neurological Sciences

Volumn 269, Issue 1-2, 2008, Pages 133-137

  Croda, Mariana Garcia ^a   de Oliveira, Augusto César Penalva ^a   Vergara, Maria Paulina Posada ^a   Bonasser, Francisco ^a   Smid, Jerusa ^a   Duarte, Alberto José da Silva ^b   Casseb, Jorge ^a,b  

^a INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Brazil; Corticosteroid; HTLV 1; Treatment; TSP HAM

Indexed keywords

BACLOFEN; CORTICOSTEROID; IVERMECTIN; METHYLPREDNISOLONE; OXYBUTYNIN; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN B GROUP;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LONG TERM CARE; MALE; MOTOR DYSFUNCTION; PHYSIOTHERAPY; PRIORITY JOURNAL; SCORING SYSTEM; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; AGED; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARAPARESIS, TROPICAL SPASTIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 43049084736     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.01.004     Document Type: Article

References (38)

1. Kaplan Je., Osame M., Kubota H., Igata A., Nishitani H., Maeda Y., et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 3 11 (1990) 1096-1101
2. Bhigjee Ai., Bill Pl., Wiley Ca., Windsor Im., Matthias Da., Amenomori T., et al. Peripheral nerve lesions in HTLV-I associated myelopathy (HAM/TSP). Muscle Nerve 16 1 (Jan 1993) 21-26
3. Iwasaki Y. Pathology of chronic myelopathy associated with HTLV-1 infection (HAM/TSP). J Neurol Sci 96 (1990) 103-123
4. Gessain A., and Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 117 11 (Dec 1 1992) 933-946
5. Osame M., Usuku K., Izumo S., Ijichi N., Amitani H., Igata A., et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1 8488 (May 3 1986) 1031-1032
6. Gotuzzo E., Cabrera J., Deza L., Verdonck K., Vandamme Am., Cairampoma R., et al. Clinical characteristics of patients in Peru with human T cell lymphotropic virus type 1-associated tropical spastic paraparesis. Clin Infect Dis 39 7 (Oct 1 2004) 939-944
7. Matsuzaki T., Nakagawa M., Nagai M., Usuku K., Higuchi I., Arimura K., et al. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirology 7 3 (Jun 2001) 228-234
8. Nakagawa M., Izumo S., Ijichi S., Kubota H., Arimura K., Kawabata M., et al. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirology 1 1 (Mar 1995) 50-61
9. Toro C., Rodes B., Poveda E., and Soriano V. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. Transplantation 75 1 (Jan 15 2003) 102-104
10. Feng J., Misu T., Fujihara K., Misawa N., Koyanagi Y., Shiga Y., et al. Th1/Th2 balance and HTLV-I proviral load in HAM/TSP patients treated with interferon-alpha. J Neuroimmunol 151 1-2 (Jun 2004) 189-194
11. Feng J., Misu T., Fujihara K., Saito H., Takahashi T., Kohnosu T., et al. Interferon-alpha significantly reduces cerebrospinal fluid CD4 cell subsets in HAM/TSP. J Neuroimmunol 141 1-2 (Aug 2003) 170-173
12. Izumo S., Goto I., Itoyama Y., Okajima T., Watanabe S., Kuroda Y., et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 46 4 (Apr 1996) 1016-1021
13. Nakagawa M., Nakahara K., Maruyama Y., Kawabata M., Higuchi I., Kubota H., et al. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurovirology 2 5 (Oct 1996) 345-355
14. Araujo Aq., Afonso Cr., Leite Ac., and Dultra Sv. Intravenous methylprednisolone in HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). Arq Neuropsiquiatr 51 3 (Sep 1993) 325-328
15. Kira J., Fujihara K., Itoyama Y., Goto I., and Hasuo K. Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci 106 1 (Nov 1991) 41-49
16. Matsuo H., Nakamura T., Tsujihata M., Kinoshita I., Satoh A., Tomita I., et al. Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy. Lancet 2 8620 (Nov 12 1988) 1109-1113
17. Kataoka A., Imai H., Inayoshi S., and Tsuda T. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. J Neurol Neurosurg Psychiatry 56 11 (Nov 1993) 1213-1216
18. Hill Sa., Lloyd Pa., Mcdonald S., Wykoff J., and Derse D. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors. J Infect Dis 188 3 (Aug 1 2003) 424-427
19. Machuca A., Rodes B., and Soriano V. The effect of antiretroviral therapy on HTLV infection. Virus Res 78 1-2 (Oct 30 2001) 93-100
20. Taylor Gp., Goon P., Furukawa Y., Green H., Barfield A., Mosley A., et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology 3 1 (Sep 19 2006) 63
21. Taylor Gp., Hall Se., Navarrete S., Michie Ca., Davis R., Witkover Ad., et al. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol 73 12 (Dec 1999) 10289-10295
22. Lehky Tj., Levin Mc., Kubota R., Bamford Rn., Flerlage An., Soldan Ss., et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 44 6 (Dec 1998) 942-947
23. Matsuzaki T., Saito M., Usuku K., Nose H., Izumo S., Arimura K., et al. A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Neurol Sci 237 1-2 (Oct 15 2005) 75-81
24. Shirabe S., Nakamura T., Tsujino A., Nishiura Y., Furuya T., Goto H., et al. Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J Neurol Sci 151 1 (Oct 3 1997) 97-101
25. Tsujino A., Nakamura T., Nishiura Y., Shirabe S., Furuya T., Goto H., et al. Pentoxifylline down-regulates adhesion molecule expression and inflammatory cytokine production in cultured peripheral blood mononuclear cells from patients with HTLV-I-associated myelopathy. J Neuroimmunol 73 1-2 (Mar 1997) 191-196
26. Araujo Ade Q., and De Andrada-Serpa Mj. Tropical spastic paraparesis/HTLV-I-associated myelopathy in Brazil. J Acquir Immune Defic Syndr Human Retrovirol 13 Suppl 1 (1996) S33-S37
27. Casseb J., Fukumori L., Vergara M., Sanabani S., Marchiori P., Duarte A., et al. Lack of tax diversity for tropical spastic paraparesis/human T-cell lymphotropic virus type 1 (HTLV-I) associated myelopathy development in HTLV-I-infected subjects in Sao Paulo, Brazil. Mem Inst Oswaldo Cruz 101 3 (May 2006) 273-276
28. Novoa P., Penalva De Oliveira Ac., Posada Vergara Mp., Da Silva Duarte Aj., and Casseb J. Molecular characterization of human T-cell lymphotropic virus type 2 (HTLV-II) from people living in urban areas of Sao Paulo city: evidence of multiple subtypes circulation. J Med Virol 79 2 (Feb 2007) 182-187
29. Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP (1990), Raven Press, New York
30. Honig Ls., Lipka Jj., Young Ky., Weiss Jh., and Foung Sk. HTLV-I-associated myelopathy in a Californian: diagnosis by reactivity to a viral recombinant antigen. Neurology 41 3 (Mar 1991) 448-450
31. Kurtzke Jf. A new scale for evaluating disability in multiple sclerosis. Neurology 5 8 (Aug 1955) 580-583
32. Sharrack B., and Hughes Ra. Clinical scales for multiple sclerosis. J Neurol Sci 135 1 (Jan 1996) 1-9
33. Lima Masd Br., and Araújo Aqc. Gender influence on the progression of HTLV-I associated myelopathy/tropical spastic paraparesis. J Neurol Neurosurg Psychiatry 76 (2005) 294-296
34. Olindo S., Cabre P., Lezin A., Merle H., Saint-Vil M., Signate A., et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol 63 11 (Nov 2006) 1560-1566
35. Casseb J., and Penalva-De-Oliveira Ac. The pathogenesis of tropical spastic paraparesis/human T-cell leukemia type I-associated myelopathy. Braz J Med Biol Res 33 12 (Dec 2000) 1395-1401
36. Araujo Aq., Leite Ac., Dultra Sv., and Andrada-Serpa Mj. Progression of neurological disability in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). J Neurol Sci 129 2 (Apr 1995) 147-151
37. Lezin A., Olindo S., Oliere S., Varrin-Doyer M., Marlin R., Cabre P., et al. Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: a new criterion for the diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis?. J Infect Dis 191 11 (Jun 1 2005) 1830-1834
38. Montanheiro Pa., Oliveira Ac., Posada-Vergara Mp., Milagres Ac., Tauil C., Marchiori Pe., et al. Human T-cell lymphotropic virus type I (HTLV-I) proviral DNA viral load among asymptomatic patients and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Braz J Med Biol Res 38 11 (Nov 2005) 1643-1647